Is Tiotropium Maintenance Therapy Necessary for All Patients With Mild to Moderate Chronic Obstructive Pulmonary Disease? The Proportion, Clinical Characteristics, and Impact Factors of Patients With a Nonrapid Decline in FEV1

被引：0
|
作者：
Wang, Z. [1 ]
Ran, P. [2 ]
Zhou, Y. [1 ]
机构：
[1] Guangzhou Med Univ Hosp, Affiliated Hosp 1, Guangzhou, Peoples R China
[2] Guangzhou Med Univ, Guangzhou Inst Resp Hlth, Affiliated Hosp 1, Natl Ctr Resp Med,Natl Clin Res Ctr Resp Dis, Guangzhou, Peoples R China
来源：
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2024年 / 209卷
关键词：
D O I：
暂无
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
A3819
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Longitudinal FEV1 dose–response model for inhaled PF-00610355 and salmeterol in patients with chronic obstructive pulmonary disease
    Jace C. Nielsen
    Matthew M. Hutmacher
    Adriaan Cleton
    Steven W. Martin
    Jakob Ribbing
    Journal of Pharmacokinetics and Pharmacodynamics, 2012, 39 : 619 - 634
  • [32] Inhaled Sodium Pyruvate Improved FEV1 and Decreased Expired Breath Levels of Nitric Oxide in Patients with Chronic Obstructive Pulmonary Disease
    Votto, John J.
    Bowen, Janet B.
    Barton, Randall W.
    Thrall, Roger S.
    JOURNAL OF AEROSOL MEDICINE AND PULMONARY DRUG DELIVERY, 2008, 21 (04) : 329 - 334
  • [33] Median regression spline modeling of longitudinal FEV1 measurements in cystic fibrosis (CF) and chronic obstructive pulmonary disease (COPD) patients
    Conrad, Douglas J.
    Bailey, Barbara A.
    Hardie, Jon A.
    Bakke, Per S.
    Eagan, Tomas M. L.
    Aarli, Bernt B.
    PLOS ONE, 2017, 12 (12):
  • [34] Longitudinal FEV1 dose-response model for inhaled PF-00610355 and salmeterol in patients with chronic obstructive pulmonary disease
    Nielsen, Jace C.
    Hutmacher, Matthew M.
    Cleton, Adriaan
    Martin, Steven W.
    Ribbing, Jakob
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2012, 39 (06) : 619 - 634
  • [35] Hospital Admission and Readmission Among US Patients Receiving Umeclidinium/Vilanterol or Tiotropium as Initial Maintenance Therapy for Chronic Obstructive Pulmonary Disease
    David Slade
    Riju Ray
    Chad Moretz
    Guillaume Germain
    François Laliberté
    Qin Shen
    Mei Sheng Duh
    Sean D. MacKnight
    Beth Hahn
    Pulmonary Therapy, 2021, 7 : 203 - 219
  • [36] Clinical Benefits Of Aclidinium Bromide Twice Daily Compared With Tiotropium Once Daily In Patients With Moderate To Severe Chronic Obstructive Pulmonary Disease
    Nakamura, H.
    Mori, Y.
    Nanki, N.
    Kamei, T.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2017, 195
  • [37] Hospital Admission and Readmission Among US Patients Receiving Umeclidinium/Vilanterol or Tiotropium as Initial Maintenance Therapy for Chronic Obstructive Pulmonary Disease
    Slade, David
    Ray, Riju
    Moretz, Chad
    Germain, Guillaume
    Laliberte, Francois
    Shen, Qin
    Duh, Mei Sheng
    MacKnight, Sean D.
    Hahn, Beth
    PULMONARY THERAPY, 2021, 7 (01) : 203 - 219
  • [38] Late Breaking Abstract - Inhaled corticosteroids (ICS), blood eosinophils (EOS), and FEV1 decline in patients with Chronic Obstructive Pulmonary Disease in a large UK primary healthcare setting
    Whittaker, Hannah
    Mullerova, Hana
    Jarvis, Deborah
    Barnes, Neil
    Jones, Paul
    Compton, Chris
    Kiddle, Steven
    Quint, Jennifer
    EUROPEAN RESPIRATORY JOURNAL, 2018, 52
  • [39] Impact of a medication therapy management service on the clinical status of patients with chronic obstructive pulmonary disease
    Kirla B. Detoni
    Isabela V. Oliveira
    Mariana M. G. Nascimento
    Thaís R. Caux
    Mateus R. Alves
    Djenane Ramalho-de-Oliveira
    International Journal of Clinical Pharmacy, 2017, 39 : 95 - 103
  • [40] Impact of a medication therapy management service on the clinical status of patients with chronic obstructive pulmonary disease
    Detoni, Kirla B.
    Oliveira, Isabela V.
    Nascimento, Mariana M. G.
    Caux, Thais R.
    Alves, Mateus R.
    Ramalho-de-Oliveira, Djenane
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2017, 39 (01) : 95 - 103
12345